Kishore M Gadde1, David B Allison. 1. Obesity Clinical Trials Programme, Duke University Medical Centre, Durham, North Carolina 27710, USA.
Abstract
PURPOSE OF REVIEW: There is a growing interest in developing combination therapies for treatment and management of obesity and related metabolic diseases. RECENT FINDINGS: Emerging data from recently completed and ongoing randomized clinical trials suggest that certain combination-drug therapies in development have greater efficacy than currently available single-drug therapies in terms of achieved weight loss and reduction in risk factors. SUMMARY: Combination-drug therapy may have a role in the treatment of obesity and related diseases as well as for prevention of risk factors. As we await safety data from studies with larger samples, the demonstrated efficacy of some of the combination drug therapies in late-stage development appears to be robust and clinically meaningful.
PURPOSE OF REVIEW: There is a growing interest in developing combination therapies for treatment and management of obesity and related metabolic diseases. RECENT FINDINGS: Emerging data from recently completed and ongoing randomized clinical trials suggest that certain combination-drug therapies in development have greater efficacy than currently available single-drug therapies in terms of achieved weight loss and reduction in risk factors. SUMMARY: Combination-drug therapy may have a role in the treatment of obesity and related diseases as well as for prevention of risk factors. As we await safety data from studies with larger samples, the demonstrated efficacy of some of the combination drug therapies in late-stage development appears to be robust and clinically meaningful.
Authors: Bryan J Sandler; Roberto Rumbaut; C Paul Swain; Gustavo Torres; Luis Morales; Lizcelly Gonzales; Sarah Schultz; Mark A Talamini; Garth R Jacobsen; Santiago Horgan Journal: Surg Endosc Date: 2015-01-29 Impact factor: 4.584